Search
Secure European Research Funding! Sign the Petition!
http://www. no-cuts-on-research. eu
EHA supports European Nobel and Fields Medal prizewinners to prevent the EU research funding for 2014-2020 from being subject to budget cuts.
International CML adherence survey launched
The drivers behind non-adherence, a highly prevalent problem in oral cancer treatments but also in many other diseases like diabetes, are not well understood to date.
Read morePersonalized medicine promises radical improvements to healthcare in Europe
And the precision that personalised medicine will bring good prospects for better use of resources.
Read moreReport Drug Shortages to EHA
In an effort to mitigate shortages of hematologic drugs in Europe, EHA is collecting and compiling reports of shortages. Are you experiencing, or foreseeing drug shortages in your clinical practice?
Please report those to drugshortage@ehaweb. org.
European Hematology Association tentatively responds to the European Commission’s proposal to improve clinical research
In addition, the regulation appears to accommodate multi-national trials with, for instance, a harmonized authorization dossier, and a single submission system.
Read moreInternational Call to Action to Alleviate Drug Shortages
The common call to action seeks first to raise awareness of shortages of drugs among hematologists.
Read moreProfessor Degos awarded at the 17th Congress of EHA in Amsterdam
Professor Degos has made a major contribution, to our understanding of the pathogenesis and treatment of acute promyelocytic leukemia (APL), to international public health and to the EHA.
Read moreJosé Carreras Award handed out at the 17th Congress of EHA
He has made seminal contributions to myeloma cell biology. These included studies of the diagnostic and prognostic roles of immunophenotyping, morphology and molecular genetics together with investigation of disease evolution and the significance of minimal residual disease.
Read moreInternational Survey of T2* Cardiovascular Magnetic Resonance in Thalassemia
Thalassemia major (TM) is a substantial health issue, with over 25,000 new transfusion- dependent children identified each year around the world.
Read moreAcute Lymphocytic Leukemia: impressive results with the monoclonal antibody blinatumomab
The Phase 2 dose-ranging study MT103-206 evaluated the efficacy, safety and tolerability of blinatumomab in adult patients with B-precursor Acute Lymphoblastic Leukemia who had relapsed following treatment with standard front-line chemotherapy or allogeneic stem cell transplant.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- 152
- 153
- 154
- 155
- 156
- 157
- 158
- 159
- 160
- 161
- 162
- 163
- 164
- 165
- 166
- 167
- 168
- 169
- 170
- 171
- »